29 May 2026
29 May 2026
Innovent Biologics will receive $650m upfront and could earn up to $9.85bn in additional milestone payments.
As the first psychedelics near approval, several other factors warrant attention to ensure effective and safe implementation.
NICE now recommends Nucala for both severe asthma and COPD, expanding the drug’s clinical uptake across the UK’s public health service.
Rising medical costs, which are caused in part by the external trade pressure in the Gulf, are a key risk factor driving household debt and widening access inequality globally.
AbbVie’s ADC has secured FDA clearance for an ultra-rare blood cancer while the agency has delayed its decision on AstraZeneca’s oral SERD for breast cancer.
The decision is anticipated by 25 November 2026.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
